Introduction 39 40
Horizontal Gene Transfer (HGT), a catch all term for the transfer of DNA between 41 individuals, is one of the main drivers of evolutionary dynamics across microbial populations 3). Although there are countless examples where HGT has been shown to increase microbial 43 fitness or enable colonization of new niches, it is increasingly appreciated that HGT brings with 44 it a variety of costs that arise as byproducts of the incorporation of foreign DNA into established 45 physiological and genetic systems (4-6). Recent efforts have begun to categorize and 46 characterize phenotypic effects of HGT across systems, and have clearly demonstrated that 47 acquisition of the same genes can lead to different outcomes across genomic backgrounds (7) . 48
Such differences in phenotypic outcomes following HGT are highly related to the concept of 49 sign epistasis in the context of de novo mutations, whereby the fitness effects of a mutation 50 change sign (e.g. from positive to negative) under specific genetic combinations (8-10). Much 51 like sign epistasis, we currently lack a general understanding of the underlying causes of 52 differences in phenotypic outcomes following HGT, and as a consequence, there is no clear 53 model for predicting if and when acquisition of DNA could be detrimental in some genomic 54 backgrounds but beneficial in others. 55 56 We have previously reported on numerous phenotypic changes that occur as a 57 consequence of acquisition of a ~1Mb megplasmid, pMPPla107, by Pseudomonas strains (11, 58 12 ). In addition to fitness costs correlated with slower growth, acquisition of pMPPla107 alters a 59 variety of other phenotypes in some strains including: increased motility, decreased biofilm 60 formation, decreased thermal tolerance, increased sensitivity to an unidentified compound 61 produced by Pseudomonads, and increased sensitivity to quinolone antibiotics like nalidixic acid 62 and ciprofloxacin. In the particular context of antibiotic sensitivity, it is important to note that 63 current annotations of megaplasmid pMPPla107 contain no known antibiotic resistance genes 64 (13) and that, at present, the mechanistic basis and overall strain specificity of these phenotypic 65 changes remains unknown. 66 67 Here, we test for how frequently sensitivity to nalidixic acid is observed across 68
Pseudomonas strains after acquisition of megaplasmid pMPPla107. We show that, although the 69 presence of this megaplasmid increases sensitivity to nalidixic acid in many strain backgrounds, 70 one strain in particular -Pseudomonas putida KT2440 -displays increased resistance to nalidixic 71 acid after this HGT event. We further demonstrate that resistance to nalidixic acid upon 72 megaplasmid acquisition is not correlated with increased resistance to ciprofloxacin, even though 73 both antibiotics affect the same cellular target. Therefore, our report provides an additional 74 example whereby the precise phenotypic effects of HGT are dependent on strain background, but 75 also suggests that that antibiotic resistance can be increased by megaplasmid pMPPla107 even in 76 the absence of identifiable resistance genes in the region acquired by HGT. These results, and 77 specifically strain-dependent changes in sign of phenotypic effects of plasmid acquisition, 78 provide new a new viewpoint for considering conditions that promote plasmid maintenance and 79 highlight the influence of genomic and environmental contexts when considering amelioration of 80 fitness costs after HGT events. All strains and plasmids used in the study are listed in Table 1 . Strain propagation of all 87 cultures largely took place at 27°C in King's B medium supplemented with rifampicin unless 88 otherwise specified. Antibiotics were supplemented into media at the following concentrations when 89 appropriate and unless otherwise specified: 50 µg/ml rifampin, 10 µg/ml tetracycline, and 20 µg/ml 90 kanamycin. Xgal was supplemented at 40 µg/ml. Antibiotic discs used in the diffusion assays 91 contained antibiotics at concentrations of 30 µg/ml for nalidixic acid and 5 µg/ml for ciprofloxacin. 92 93 Kirby-Bauer Disc Diffusion Assays 94 95 Strains of interest for each assay were streaked from frozen stocks and incubated on KB 96 media at 27°C for 2 or 3 days. At this point a small clump of cells was picked to liquid KB medium 97 and grown for 48 hours at 27°C with shaking. Cells from each culture where then pelleted in a 98 centrifuge, the supernatant was poured out, and pelleted cells were resuspended in 10Mm MgCl2 for 99 measurement of OD600. Each culture was then diluted to 0.01 OD600 in 10Mm MgCl2 and 300uL of 100 each culture was added to 3mL of 0.4% water agar (which was previously melted and allowed to 101 briefly cool so that it was warm to the touch). This bacteria/agar mixture was then poured onto a 102 plain KB agar plate (1.5% agar) and allowed to solidify. Lastly, a disc containing the antibiotic of 103 interest was added to the center of the plate and each was placed in an incubator at 27°C. Pairs of 104 megaplasmid +/-strains were always evaluated together within the same assay. 105
After 3 days of growth, each plate was taken out of the incubator and scanned. This scanned 106 image was imported into ImageJ (14) , and the area of the inhibition zone was measured. An average 107 area was calculated for the megaplasmid-strain within each assay, and individual data points for 108 each pair of megaplasmid + and -strains in each assay were divided by this value in order to 109 normalize the data, Therefore, the average inhibition zone for each megaplasmid-strain within each 110 assay was normalized to a value of 1. 111 112 Competitive Fitness Assays 113 Strains of interest for each assay were streaked from frozen stocks for 2 or 3 days (on media 114 containing kanamycin for megaplasmid+ strains) after which point a small clump of cells was picked 115 to liquid KB medium and grown for 24 hours at 27°C with shaking. Cells from each culture where 116 then pelleted in a centrifuge, the supernatant was poured out, and pelleted cells were resuspended in 117 10Mm MgCl2 for measurement of OD600. Each culture was then diluted to 1.0 OD600 in 10Mm 118
MgCl2. 119 A 10mL master culture was prepared for each set of comparative fitness assays. To prepare 120 this master culture, 5uL of each 1.0 OD600 dilution of the two comparison strains within each assay 121 was added to the 10mL master culture. At this point, 2mL samples of this master culture were added 122 to 4 different test tubes, and the test tubes were placed in a shaking incubator and grown for 24 hours 123 at 27°C. For day 0 measurements the master mix culture was diluted 1:100 by adding 10µL into 124 990uL10Mm MgCl2, which was followed by an additional 1:10 dilution. 3 replicate dilution series 125 were made from each master mix culture, and 150µL of each 1:100/1:1000 dilution was plated on LB 126 media containing 40µg/ml Xgal and placed 27°C. After 24 hours of growth each of the 4 replicate 127 cultures was diluted 1:10,000,000 and 1:100,000,000, with 150µL of these dilutions plated on LB 128 media containing 40µg/ml Xgal and placed at 27°C. 129
White and blue colonies were independently counted for each of the plated day 0 dilutions, 130 the 3 values were averaged together, and the log10 value of this average taken as the day 0 colony 131 forming unit count. White and blue colonies were independently counted for each of the day 1 132 replicate cultures and log10 transformed. Relative fitness was calculated as the ratio of the difference 133 between log10 transformed white and blue colony counts for each replicate culture at day 1 over the 134 difference of the log10 transformed average white and blue colony counts at day 0. Two assays were 135 carried out with each pair of strains (DBL305/DBL1604 and DBL305/DBL1620), with four replicate 136 cultures per assay. 137
Relative fitness was measured in the same way in cultures supplemented with nalidixic acid, 138 except that 5µL samples of each strain were independently added to separate master mix cultures for 139 each antibiotic concentration. Additionally, given that cultures grew more slowly in the presence of 140 pMPPla107 increases nalidixic acid sensitivity in Pseudomonas stutzeri 28a84 (12), and here we 155 demonstrate that this effect is replicated by a simple modified assay based on Kirby-Bauer disc 156 diffusion assays ((16), Figure 1A ). Since antibiotics diffuse out from the disc into the media 157 forming a concentration gradient, size of the inhibition halo is positively correlated with 158 backgrounds of P. stutzeri strain 28a24, DBL332 and DBL386. Derivative strains of these 160 (DBL453 and DBL408, respectively, which contain megaplasmid pMPPla107) have a larger 161 halo of inhibition around the antibiotic disc containing nalidixic acid than their immediate 162 progenitor strains which lack megaplasmid pMPPla107 ( Figure 1B ). There is an overall 163 significant effect of megaplasmid on nalidixic acid sensitivity (F1,36=132.143, p<0.0001), and 164 there are clear statistical differences between the areas of the inhibition halos for each pair of 165 megaplasmid -/+ strains measured separately (DBL332/DBL453, t-test p<0.001; 166 DBL386/DBL408, t-test p<0.001). Therefore the acquisition of this megaplasmid sensitizes these 167 strains to this antibiotic. 168 169 Acquisition of pMPPla107 Sensitizes Most, But Not All, Strains to Nalidixic Acid 170 171 Extending the Kirby-Bauer diffusion assay design, we tested for sensitivity to nalidixic 172 acid across a variety of other Pseudomonas stutzeri strains as well as a P. syringae pv. 173 lachrymans 8003. The P. syringae strains are relatively closely related to the strain in which this 174 megaplasmid was originally found, P. syringae pv. lachrymans 107 (17). Overall, we find that 175 megaplasmid acquisition increases sensitivity to nalidixic acid across all of these strains as 176 reflected by increased halo size in these Kirby-Bauer assays ( Figure 2 ). However, we also find 177 that the magnitude of this difference appears to be smaller in P. syringae than across all of the P. 178 stutzeri strains. All comparisons between megaplasmid-and megaplasmid+ strains are 179 significantly different (t-test, p<0.001 for each). 180
Using the same diffusion assays as above, we find that acquisition of megaplasmid 185 pMPPla107 by Pseudomonas putida KT2440 repeatedly increased resistance of this strain to 186 nalidixic acid (as reflected by a smaller halo in megaplasmid+ strains in Figure 3 ). This effect 187 was replicated in an independently created pair of P. putida strains originally derived from P. 188 putida KT2442, where megaplasmid pMPPla107 was tagged with a different marker ( Figure 3 ). 189
Nalidixic acid and ciprofloxacin are both quinolone antibiotics that have the same 190 mechanism of action and cause bacterial cell death by inhibiting the ability of gyrase to 191 covalently connect DNA strands after unwinding. Using the same Kirby-Bauer diffusion assays 192 as above, but instead replacing nalidixic acid discs with ciprofloxacin discs, we find that 193 acquisition of megaplasmid pMPPla107 does not increase resistance to this antibiotic ( Figure 3) We have previously shown that acquisition of pMPPla107 by P. stutzeri 28a84 leads to 203 dramatic fitness costs when measured by growth rate and by competitive fitness assay, and have 204 demonstrated that growth in the presence of nalidixic acid increases this fitness cost (11, 12). We 205 therefore carried out competitive fitness assays of differentially marked P. putida strains in order 206 to test whether megaplasmid acquisition also affected competitive growth in this strain 207 background, and likewise how competitive fitness might change in the presence of nalidixic acid. 208
As one can see in Fig. 4A , there is no measurable difference in competitive fitness between the 209 lacZ+ background (KT2442) and the wild type background (KT2440) (t-test compared to value 210 of 1, p=0.14). However, in media without any antibiotic supplementation, megaplasmid 211 acquisition leads to a ~10% loss in competitive fitness over one growth cycle ( Figure 4A ), and 212 this difference is significantly different from the control comparison (F2,17=264.82, p<0.0001). 213 Therefore, increased nalidixic acid resistance as seen in the assays above occurs even though 214 megaplasmid acquisition significantly lowers strain growth rates in the absence of antibiotic. Since megaplasmid acquisition by P. putida appears to increase nalidixic acid resistance 220 according to Kirby-Bauer diffusion assays, we tested whether supplementation of media with 221 nalidixic acid could shift the outcomes of competitive fitness assays between wild type and a 222 megaplasmid containing strain. In the absence of any antibiotic supplementation, we are able to 223 independently recapitulate the fitness costs of megaplasmid acquisition reported above, and 224 again find a significant cost of megaplasmid acquisition when measured by competitive fitness 225 ( Figure 4B ). However, fitness relationships between strain pairs that lack or contain the 226 megaplasmid shift when nalidixic acid is supplemented into media. At 20µg/ml, a ~10% fitness 227 cost of the megaplasmid changes to a slight benefit for carriage of the plasmid. Moreover, we see 228 increasing fitness according to these competitive assays for the megaplasmid strain at even 229 higher levels of nalidixic acid (40µg/ml), although the exact magnitude of this effect appears to 230 be quite variable ( Figure 4B ). Competitive Fitness measurements are significantly different 231 between each concentration of antibiotics (TukeysHSD, p<0.02). Therefore, megaplasmid 232 acquisition by P. putida significantly increases resistance to nalidixic acid as measured by both 233
Kirby-Bauer diffusion assays as well as by competitive fitness assays. 234 235 Discussion 236
237
There is a growing interest in predicting the evolutionary dynamics within microbial 238 populations, as a means to drive evolution within populations and communities towards 239 beneficial outcomes as well as a way to control or limit change within extant populations (18). 240
Horizontal Gene Transfer (HGT) is well recognized as a powerful driver of evolutionary 241 dynamics within microbial communities (1) (2) (3) , and as such, should be incorporated into 242 scenarios for predicting future evolutionary dynamics in natural communities. Plasmid 243 conjugation and acquisition is a major contributor to HGT in bacterial populations and 244 communities, and plasmids are well known to provide large-scale evolutionary benefits like 245 enabling antibiotic resistance (2, 3, 19). However, plasmid carriage can also entail a variety of 246 fitness costs, which can be manifest as lowered fitness or other phenotypic changes for plasmid 247 bearing strains, in specific environments (4-6). The presence of costs associated with plasmid 248 carriage has led to speculation about the conditions that enable plasmid maintenance within 249 populations through time, with one likely scenario being that costs associated with plasmid 250 carriage are ameliorated over time through subsequent and potentially rapid compensatory 251 adaptation (20, 21). Although not all HGT events entail fitness costs, rapid amelioration of 252 fitness costs associated with plasmid acquisition could lead to genetic and phenotypic tradeoffs 253 that fundamentally shift future evolutionary trajectories for the affected populations. As such, 254 and with a lofty goal of ultimately being able to predict evolution across bacterial populations, it 255 is therefore critical to understand how costs of plasmid carriage are affected by genetic, genomic, 256 and environmental contexts. 257
258
Here we demonstrate that the direction of one previously observed phenotype associated 259 with acquisition of megaplasmid pMPPla107, sensitivity to nalidixic acid in Pseudomonas (12), 260 depends upon the interactions between this megaplasmid and genomic background of the strain 261 of interest. Across almost all surveyed strains, acquisition of pMPPla107 sensitizes cells to 262 nalidixic acid but in P. putida KT2440 this same horizontal transfer event increases resistance to 263 this antibiotic. These contrasting phenotypic effects occur in the absence on this megaplasmid of 264 identifiable genes known to influence antibiotic sensitivity and resistance. Thus, this is not 265 simply a scenario where a common antibiotic resistance gene found on the megaplasmid is active 266 in one background compared to the others, but rather a situation where the phenotypic effects of 267 genes present on a megaplasmid are polar opposites under certain environments in ways that 268 depend on the chromosomal background. Also important, these same phenotypic effects are not 269 seen when strains are challenged with ciprofloxacin, an antibiotic that is structurally different 270 than but which has the same mechanism of action as nalidixic acid as P. putida KT2440 displays 271 either no change or a slight sensitivity to ciprofloxacin after acquisition of megaplasmid 272 pMPPla107. Therefore, these results imply that the mechanism underlying changes in sensitivity 273 to nalidixic acid and/or ciprofloxacin are not simply due to alterations in gyrase and 274 topoisomerase activity within a cell due to the presence of an additional 1Mb of DNA. As we 275 have demonstrated previously in P. stutzeri, we further show that acquisition of megaplasmid 276 pMPPla107 is associated with a large (~10%) fitness cost in P. putida in conditions without 277 antibiotic supplementation. Therefore, differing responses to nalidixic acid cannot simply be 278 explained as a secondary consequence of overall growth defects due to acquisition of 279 pMPPla107 and there must be some other inherent systems level effect that creates opposing 280 phenotypic responses across strain backgrounds upon acquisition of this megaplasmid. 281
282
Quinolone antibiotics have been used as a means of curing a variety of plasmids from 283 many different bacterial strains, which implies that plasmid driven sensitivity to quinolones 284 could be a widespread phenomenon (22). These previously reported effects are thought to be 285 mediated by stress at the level of gyrase and topoisomerase function and should therefore likely 286 be affected by either nalidixic acid or ciprofloxacin (22) . At present there are no clear 287 mechanistic explanations for differing phenotypic responses of Pseudomonas strains to 288 acquisition of pMPPla107 and any potential scenario must involve interactions between genes on 289 both the chromosome and megaplasmid with one outcome of this interaction being differential 290 sensitivity to nalidixic acid but not ciprofloxacin. While annotations of pMPPla107 do not point 291 to any genes directly implicated in nalidixic acid resistance (13), these same annotations do 292 suggest that the megaplasmid contains multiple efflux pumps. While the substrates for these 293 pumps are currently unknown, it is plausible that one could differentially transport nalidixic acid 294 and not ciprofloxacin outside of the cell. Indeed, there is precedence for efflux pumps in 295
Pseudomonas aeruginosa and other bacteria to differentially transport quinolone antibiotics (23, 296 or activity of this pump for nalidixic acid differs based on chromosomal background. There may 298 also be a mechanism to differentially detoxify nalidixic acid that resides on the chromosome 299 (whether through efflux pumps or other means), but where the activity of which is differentially 300 affected by megaplasmid encoded pathways. Perhaps there is a global regulator which is 301 similarly affected by megaplasmid presence, but where the downstream phenotypic effects differ 302 across strain backgrounds. For example, megaplasmid presence could uniformly lead to 303 upregulation of AmrZ across Pseudomonads, but upregulation of AmrZ may trigger opposing 304 phenotypic effects in the context of nalidixic acid resistance in different strain backgrounds (25). 305
It is also possible that phenotypic outcomes of increased sensitivity and resistance to nalidixic 306 acid in the presence of pMPPla107 are due to mechanistically different effects. Under this case, 307 the default condition might be that plasmid acquisition causes cells to become more sensitive to 308 certain antibiotics, but that in some backgrounds (in this case P. putida) there is an additional 309 pathway or efflux pump that is differentially affected by megaplasmid presence and which 310 enables cells to overcome sensitization found in other Pseudomonas species. 311 312 Specific evolutionary responses to selective pressures are driven by the availability of 313 adaptive mutations within the context of an adaptive landscape (26). Costs associated with 314 plasmid acquisition can rapidly be ameliorated by new mutations that occur on either the plasmid 315 or throughout the rest of the genome, with the speed of compensation correlated with selection 316 pressures acting on the plasmid bearing population (20, 21). Extrapolation from work focused on 317 the molecular and theoretical basis of adaptation predicts that the target size or number of 318 potential compensatory mutations should increase with the cost of plasmid carriage (27). Given 319 costs of plasmid carriage change depending on the environment, it is therefore likely that both 321 the speed and molecular basis of amelioration of plasmid costs will greatly differ across 322 environments. Likewise, since the costs and phenotypic consequences of plasmid carriage differ 323 dramatically across genomic backgrounds, there will likely be substantial variation in both the 324 evolutionary paths and molecular basis of compensatory mutations for the exact same plasmid 325 within different strains. Likewise, the phenotypic effects reported here suggest that plasmids 326 could be differentially maintained or lost across bacterial populations in ways that depend on 327 genotype by environment interactions rather than on simply based on the presence or absence of 328 beneficial genes. Results presented here therefore also strongly bear on our understanding and 329 predicting the evolutionary forces that enable plasmid sharing across microbial communities. 330
331
The phenomenon reported here also suggests that plasmid acquisition could 332 fundamentally change evolutionary dynamics of antibiotic resistance in a strain dependent way. 333 For instance, there will likely be a different suite of resistance mutations available towards 334 nalidixic acid in P. putida KT2440 depending on whether this genomic background contains 335 pMPPla107 or not. This is very much in the vein of sign epistasis when discussing phenotypic 336 effects of de novo mutation and evolutionary pathways of adaptation (8, 9, 28, 29) . It is also 337 currently unknown how phenotypic effects of particular resistance mutations are altered in the 338 presence of this megaplasmid. Given that there will likely be tradeoffs in gyrase activity with 339 mutations towards quinolone resistance, one could envision scenarios where acquisition of this 340 megaplasmid simply adds to the level of resistance to nalidixic acid, has no phenotypic effect in 341 a background that already contains nalidixic acid resistance mutations, or even sensitizes cells to 342 nalidixic acid at 100ng/uL, it is possible that further acquisition of pMPPla107 may either 344 provide no benefit (MIC+pMPPla107=100ng/uL), an additive increase to resistance 345 (MIC+pMPPla107>100ng/uL), or sensitizes this strain (MIC+pMPPla107<100ng/uL). Future 346 experiments will be necessary to differentiate between these possibilities. 347
348
In conclusion, we report here that acquisition of megaplasmid pMPPla107 leads to 349 opposing phenotypic effects of strains in the presence of nalidixic acid but not ciprofloxacin. In 350 most Pseudomonas strains, there is a cost to acquisition of pMPPla107 in that cells containing 351 this megaplasmid are sensitized to this antibiotic. However, at least in P. putida, acquisition of 352 pMPPla107 increases resistance to nalidixic acid in the absence of identifiable genes involved in 353 antimicrobial resistance. We highlight that these results of HGT are analogous to the 354 phenomenon of sign epistasis when discussing phenotypic effects of de novo mutations within a 355 genome. Therefore, as with sign epistasis, it is therefore likely that some HGT events will lead to 356 fundamental shifts in the adaptive landscape in ways that depend on both the genomic 357 background and environment. Depending on how widespread such results are, context 358 dependence of phenotypic effects will potentially increase uncertainty in models and predictions 359 for the evolutionary dynamics of microbial adaptation after horizontal gene transfer events as 360 well as antimicrobial resistance. 361 365 366 367
Figure 1. Kirby-Bauer Diffusion Assays Recapitulate A Nalidixic Acid Sensitivity
Phenotypes in Pseudomonas stutzeri. A) Representative scans from a disc diffusion assay from using (from left to right) a strain that either lack (DBL386) or contain (DBL408) megaplasmid pMPPla107. Image areas covered by each of these two representative pictures (grey), the sensitivity halo around the disc containing nalidixic acid and strain DBL386 (black) or strain DBL408 (white) are overlaid onto each other at the far right of this image. B) Data from disc diffusion overlay assays comparing P. stutzeri strains DBL332 and DBL386 with derivatives which have acquired megaplasmid pMPPla107. Each strain was assayed at least three independent times, with at least 2 (but usually 6) replicates per strain per assay. Halo size was normalized to the relevant "wild type" strain within each assay (DBL332 for DBL453, DBL386 for DBL408) and plotted on the Y-axis. Individual data points are shown for all assays, with box hinges corresponding to first and third quartiles and mean plotted as horizontal lines in the center of the boxes. Strains containing the megaplasmid are more sensitive to inhibition by nalidixic acid (F1,36=132.143, p<0.0001). Additionally, there are clear statistical differences between the areas of the inhibition halos for each pair of megaplasmid -/+ strains (DBL332/ DBL453, t-test p<.001; DBL386/DBL408, t-test p<0.001).
Figure 2. Acquisition of Megaplasmid pMPPla107
Sensitizes Numerous Pseudomonas strains to Nalidixic Acid. Data is shown for disc diffusion overlay assays comparing P. stutzeri strains DBL880, DAB282, DBL883, and DBL885 with derivatives which have acquired megaplasmid pMPPla107 (DBL907, DBL287, DBL910, DBL912 respectively). Data is also shown for derivatives of P. syringae pv. lachrymans strain 8003 which either lack (DBL462) or contain (DBL895) megaplasmid pMPPla107. Strain names of those lacking the megaplasmid are shown in grey boxes. Each strain was assayed at least three independent times, with at least 4 (but usually 6) replicates per strain per assay. Two additional assays were performed for P. syringae strains. Halo size was normalized to the relevant "wild type" strain within each assay and plotted on the Y-axis. Individual data points are shown for all assays, with box hinges corresponding to first and third quartiles and mean plotted as horizontal lines in the center of the boxes. In each case, presence of megaplasmid pMPPla107 sensitizes strains to nalidixic acid as shown by increased halos of inhibition. All intrastrain comparisons between parent strains that lack the megaplasmid and derivative strains containing the megaplasmid are significantly different (p<0.001) by t-test.
Figure 3. Acquisition of Megaplasmid pMPPla107 by P. putida Increases Resistance to
Nalidixic Acid but Not Ciprofloxacin. Data is shown for disc diffusion overlay assays comparing P. putida strains DBL305 (KT2440) and DBL1604 (KT2442) with derivatives which have acquired megaplasmid pMPPla107 (DBL759 and DBL1620 respectively). Each strain was assayed at least three independent times for each antibiotic, with 6 replicates per strain per assay. Halo size was normalized to the relevant "wild type" strain within each assay and plotted on the Y-axis. Individual data points are shown for all assays, with box hinges corresponding to first and third quartiles and mean plotted as horizontal lines in the center of the boxes. A) Presence of megaplasmid pMPPla107 increases resistance of P. putida strains to nalidixic acid as shown by decreased halos of inhibition (F1,85=147.57, p<0.0001). Moreover, there are clear statistical differences between the areas of the inhibition halos for each pair of megaplasmid -/+ strains (DBL305/DBL759, ttest p<.001; DBL1604/DBL1620, ttest p<0.001) B) Presence of megaplasmid pMPPla107 appears to sensitize P. putida strains to ciprofloxacin as shown by increased halos of inhibition (F1,80=12.99, p<0.001). However, although ciprofloxacin halo inhibition areas statistically differ between strains DBL305 and DBL759 (ttest, p<0.001), there is no clear difference in the inhibition halos between strains DBL1604 and DBL1620 (ttest, p=0.29). Competitive fitness assays in liquid KB media were carried out between strain DBL305 (P. putida KT2440) and lacZ+ strains that either lack (DBL1604) or contain (DBL1620) megaplasmid pMPPla107. At least two competitive fitness assays were carried out for each pairing with 4 replicates per assay in all but one case (one assay at Nal40 only had 3 replicates) Individual data points are shown for all assays, with box hinges corresponding to first and third quartiles and mean plotted as horizontal lines in the center of the boxes. A) Although there is no measurable difference in competitive fitness due to the lacZ+ marker (assays between DBL305 and DBL1604), presence of the megaplasmid leads to a ~10% fitness cost during growth in KB medium. B) Although the ~10% fitness cost of the megaplasmid again apparent during competition between DBL305 and DBL1620 in unsupplemented KB medium, strain 1620 (containing megaplasmid pMPPla107) display increasingly higher relative fitness compared to strain DBL305 when media is supplemented with nalidixic acid at either 20 or 40 ng/uL. Comparisons between all strains within each subfigure are significantly different according to Tukey's HSD at p<0.05.
